Category: GLOBE-NEWSWIRE

April 17, 2023

• Market-leading Philips PACS is now available on AWS for industry-leading availability, reliability, security, and AI-supported workflow enhancements
• Expansion of the collaboration with AWS will support the development and deployment of generative AI applications that further support efficient clinical workflows and enhance diagnostic capabilities

Amsterdam, the Netherlands and Chicago, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology today announced the availability of Philips HealthSuite Imaging on Amazon Web Services (AWS). Additionally, Philips and AWS will build on their relationship, advancing AI in healthcare by applying Foundation Models using Amazon Bedrock to accelerate the development of cloud-based generative AI applications that will provide clinical decision support, help enable more accurate diagnoses, and automate administrative tasks.

The availability of Philips HealthSuite Imaging on AWS is a new addition to Philips’ broad capabilities in enterprise informatics, enabling improved image access speeds, reliability, and data orchestration for radiologists and clinicians across the entire imaging workflow – from diagnosis to therapy selection, treatment and follow-up. Clinicians will be able to access the latest innovations from any location, and healthcare organizations can reduce costs previously invested in on-premises hardware or data centers to host their image management platform.

Philips can help clinicians manage growing workloads amidst staff shortages and speed time to diagnosis and treatment, enhancing patient outcomes. Philips HealthSuite Imaging will use Amazon HealthLake Imaging to increase scale, deliver fast time to first image, enable easy re-use of images for Machine Learning and research, and reduce medical imaging costs.

Philips will also use Amazon Bedrock as part of its efforts to develop generative AI applications to advance PACS image processing capabilities and simplify clinical workflows and voice recognition. Amazon Bedrock will enable Philips to develop Machine Learning-based applications quickly and reduce model development costs versus building Foundational Models (FMs) from scratch or running multiple task-specific model development efforts.

“With healthcare systems under increasing pressure, the focus of clinicians’ has shifted from technical specifications towards more efficient workflows that lead to accurate diagnoses – and that’s what we are delivering here,” said Shez Partovi, Chief Innovation & Strategy Officer and Business Leader Enterprise Informatics at Philips. “By shifting from on-premises to the cloud, we can leverage the security, reliability, and unmatched breadth and depth of AWS to support healthcare organizations in their mission to deliver high quality care while easing the burden on their staff.”

“Healthcare organizations are looking for ways to decrease operational costs, improve health data interoperability, and enable data-driven decision making for clinicians to improve access to quality patient-centered care,” said Swami Sivasubramanian, vice president of database, analytics, and machine learning at AWS. “Through democratizing access to generative AI and applying FMs to help support clinical decision-making, increase diagnostic accuracy, and automate administrative tasks, AWS will continue to support Philips as they uncover new ways to simplify radiologists’ workflow and reduce cognitive burden and clinician burnout.”

Philips and AWS provide migration expertise and planning services, total-cost-of-ownership analysis, and cybersecurity technical expertise to enable an easy migration from on-premises to cloud-based solutions for customers.

To learn more about Philips’ enterprise informatics portfolio, join Philips in person at HIMSS23 at booth #901 or visit Philips’ virtual informatics experience and follow @PhilipsLiveFrom for #HIMSS23 updates throughout the event.

For further information, please contact:

Anna Hogrebe
Philips Global Press Office
Tel.: +1 416 270 6757
Email: anna.hogrebe@philips.com

Joost Maltha
Philips Global Press Office
Tel: +31 6 10 55 8116
Email: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at http://www.philips.com/newscenter.

Attachments

• Clinicians review a worklist screen with Philips VuePACS
• IntelliSpace PACS Universal Data Manager

GlobeNewswire Distribution ID 1000804279

• To be published on quarterly basis, with updated average sales price (ASP) and National Average Drug Acquisition Cost (NADAC) trends
• Biosimilars continue to play a crucial role in driving down healthcare costs

INCHEON, Korea, April 17, 2023 (GLOBE NEWSWIRE) — Samsung Bioepis Co., Ltd. today released the first edition of its Biosimilar Market Report which explores latest market trends for all biosimilars commercially available in the United States. The first quarterly report details the most recent price trends of all molecules for which biosimilars have launched, along with insights into interchangeability of biosimilars.

“The first edition of Biosimilar Market Report from Samsung Bioepis reveals that market competition stimulated by the introduction of biosimilars in the US has contributed to significant price reductions in the biologics market. However, the level of biosimilar usage varies by molecule, with some still taking less than 50% of the market share. This indicates that there is still room for greater cost savings in therapeutic areas such as supportive care, immunology, and ophthalmology,” said Tom Newcomer, Vice President, Head of Market Access, US, at Samsung Bioepis. “Biosimilars continue to play a crucial role in driving down healthcare costs in the US and we hope this report provides an insightful context into the forefront of the US biosimilar market landscape,” he added.

The key findings of the Report are as follows:

• Increased biosimilar usage is correlated to lower cost, with oncology (trastuzumab, bevacizumab, rituximab) biosimilars being more price sensitive than supportive care (filgrastim, pegfilgrastim, epoetin alfa) or immunology (infliximab).
• On average, biosimilars gained 53% market share three years after their initial launch. Oncology and pegfilgrastim have seen faster acceptance (75%) of biosimilars compared to other therapeutic areas.
• Biosimilar launches have led to significant price decreases over time. ASPs declined 41% on average three years after first biosimilar launch. ASPs for oncology biosimilars experienced the steepest decline, with each dropping over 50% in the first three years after biosimilar launch.
• Insulin glargine and adalimumab categories reflect recent pricing practices such as unbranded biologics and high/low wholesale acquisition cost (WAC) options. The report analyzes national average drug acquisition costs (NADAC) for products under the pharmacy benefit, whose findings indicate the potential for deep discounts and savings in insulin and adalimumab classes.¹

Going forward, Samsung Bioepis Biosimilar Market Report will be published every quarter after the Center of Medicare, Medicaid Services (CMS) publishes updated ASP values for each product. To access the full report, please visit https://www.samsungbioepis.com/upload/attach/SB+Biosimilar+Market+Report+Q2+2023.pdf.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter, LinkedIn.

References:

¹ There is no ASP data publicly available for products under the pharmacy benefit, so NADAC was used to analyze the net price of products under the pharmacy benefit.

MEDIA CONTACT

Anna Nayun Kim, nayun86.kim@samsung.com

Jane Chung, ejane.chung@samsung.com

GlobeNewswire Distribution ID 8808799

ATLANTA and LIER, Belgium, April 17, 2023 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX:DSG), announced today that the Descartes eBookings for Ocean Shipment Management solution is now an SAP Endorsed App, available for online purchase on SAP^® Store. SAP Endorsed Apps are a category of solutions from SAP’s partner ecosystem that help customers become best-run, intelligent enterprises. Endorsed apps are meant to deliver value with desired outcomes.

“We’re delighted to announce that Descartes eBookings for Ocean Shipment Management is an SAP Endorsed App,” said Kenneth Wood, Executive Vice President, Product Management at Descartes. “The ability of Descartes eBookings for Ocean Shipment Management to connect carriers across the globe and transform shipment data helps manufacturers, retailers and distributors digitize their supply chain operations.”

SAP Endorsed Apps are premium certified by SAP with added security, in-depth testing and measurements against benchmarks results. Descartes eBookings for Ocean Shipment Management is part of the Descartes Global Logistics Network and is integrated with the SAP Logistics Business Network. The combination expands customers’ ocean shipment management capabilities, uniting multiple parties and processes together from the contract to booking phase through the tracking and financial settlement lifecycle. Descartes eBookings for Ocean Shipment Management is a cloud-based, proven solution that enhances SAP TM via SAP Business Network Freight Collaboration to execute bookings and provide shipment status visibility information.

“Ecosystem innovations are essential to SAP’s vision and delivery of the intelligent enterprise for SAP customers,” said Darryl Gray, Global Vice President, Software Partner Solution Monetization & Success at SAP. “We applaud Descartes on achieving SAP Endorsed App status for the Descartes eBookings for Ocean Shipment Management solution. Partners like Descartes are positioned to help us deliver a cloud-first strategy with integrated innovations, proven to provide value while solving key business challenges.”

The Descartes eBookings for Ocean Shipment Management solution is available for digital discovery and purchase at SAP Store, the digital marketplace for solutions from SAP and its partners. SAP Store provides customers with real-time access to more than 2,000 innovative solutions from SAP as well as partner solutions that complement and extend their SAP applications, enabling digital transformation of their business.

About Descartes

Descartes is the global leader in providing on-demand, software-as-a-service solutions focused on improving the productivity, security, and sustainability of logistics-intensive businesses. Customers use our modular, software-as-a-service solutions to route, track and help improve the safety, performance and compliance of delivery resources; plan, allocate and execute shipments; rate, audit and pay transportation invoices; access global trade data; file customs and security documents for imports and exports; and complete numerous other logistics processes by participating in the world’s largest, collaborative multimodal logistics community. Our headquarters are in Waterloo, Ontario, Canada and we have offices and partners around the world. Learn more at www.descartes.com, and connect with us on LinkedIn and Twitter.

SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices.

Global Media Contact
Cara Strohack
Tel: +1(800) 419-8495 ext. 202025
cstrohack@descartes.com

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ solution offering and potential benefits derived therefrom; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities commissions across Canada including Descartes most recently filed management’s discussion and analysis. If any such risks actually occur, they could materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

GlobeNewswire Distribution ID 8808217

– Designed to deliver coordinated blockade of PD-1/PD-L1 pathway with targeted, enhanced IL-18 signaling to critical antitumor effector cells –

– T cells co-expressing PD-1 and IL-18 receptors are highly enriched in the tumor microenvironment (TME) versus peripheral blood, providing rationale for tumor-selective targeting with BPT567 –

– Marked expansion of CD8+ T-cells and reduction of regulatory T-cells, with mediation of tumor regression via CD8+ T-cell dependent mechanism(s) –

SAN DIEGO and BASEL, Switzerland, April 17, 2023 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a biotechnology company developing multifunctional precision immunotherapies for cancer and autoimmune disease, today announced the presentation of new data characterizing the highly targeted biological and therapeutic effects of BPT567 that contribute to its potent single agent anti-tumor activity at the American Association for Cancer Research (AACR) Annual Meeting being held on April 14-19, 2023, in Orlando, FL.

Bright Peak has leveraged its world-class protein engineering capabilities to functionally optimize the master cytokine IL-18, creating an IL-18 binding protein-resistant molecule with enhanced affinity for the IL-18 receptor, and integrate it with PD-1 checkpoint blockade to create a first-in-class PD1-IL18 immunocytokine, BPT567. “BPT567 is designed to coordinately engage antigen-experienced T_eff cells that are known to co-express both PD-1 and the IL-18 receptor. These T-cells have been reported to be highly cytotoxic and enriched in the tumor microenvironment, and as a PD1-IL18 immunocytokine, BPT567 is uniquely targeted to these cells,” said Jon Wigginton, M.D., President of Research and Development of Bright Peak Therapeutics. “Upon further characterization of the biological activity of BPT567 in preclinical tumor models, we found that it was indeed able to more selectively target the potent pro-inflammatory effects of IL-18 to the tumor with limited activation of immune cells in the periphery. It is anticipated that this could ultimately contribute to an improved risk-benefit profile for BPT567 in the clinical setting.”

Details regarding the upcoming AACR abstract presentations are as follows:

April 17, 2023, 9:00 AM – 1:30 PM (EST)
Poster 1850: A First-in-Class PD1-IL18 Immunocytokine (BPT567) Targets PD-1⁺ IL18R⁺ CD8⁺ T Effector Cells Enriched in the Tumor Microenvironment and Exhibits Potent Antitumor Efficacy With Excellent Tolerability

Abstract Highlights: Bright Peak’s unique protein engineering and chemical conjugation platform enables the generation of immunocytokines (ICs) via rapid and site-specific conjugation of optimized cytokines to the Fc domain of existing human antibodies. IL-18 is a master proinflammatory and antitumor cytokine that integrates and stimulates both innate and adaptive immunity and activates antigen-experienced T cells marked by IL-18 receptor (IL-18R) expression, making it an ideal payload to generate an oncology IC. BPT567 is a multifunctional, PD-1 targeted IL-18 based IC consisting of an optimized IL-18 payload with enhanced affinity for IL-18R and significant resistance to the neutralizing factor IL-18 binding protein (IL-18BP), then conjugated to a clinical stage anti-human PD-1 antibody (lipustobart). BPT567 is designed to deliver coordinated PD-1/PD-L1 blockade and IL-18 signaling to the same cell (cis-signaling), with targeting and activation of PD-1⁺ IL-18R⁺ (“double-positive”) CD8⁺ T cells that have been reported to be highly cytotoxic and enriched in the tumor microenvironment (TME).

BPT567 demonstrated significantly greater stimulation of IL-18 induced IFNγ release on PD-1^high versus PD-1^low immune cells in vitro, consistent with cis-signaling-mediated enhancement of potency. In pharmacodynamic (PD) studies performed on MC38 tumor-bearing transgenic mice expressing human PD-1, significant expression of both PD-1 and IL-18R was detected in T cells within the tumor, whereas immune cell populations in the blood expressed low levels of either PD-1 or IL-18R but not both. Detailed characterization revealed that enrichment of simultaneous PD-1 and IL-18R expression occurred principally within CD8 and CD4 memory T cells within the tumor. Accordingly, after BPT567 administration, marked expansion of CD8+ effector memory cells was observed within the tumor with minimal expansion in the blood, while the proportion of regulatory T cells (Tregs) was significantly suppressed in the tumor and unchanged in the blood. Concurrent with these changes in the composition of tumor-infiltrating lymphocytes, BPT567 induced significant release of proinflammatory cytokines within the tumor, including IFNγ, TNF, and GM-CSF, with a far lower extent of cytokine release in the periphery. In preclinical tumor models, administration of BPT567 mediated synergistic antitumor activity that was superior to anti-PD-1 alone, a control non-targeted HER2 IL-18 IC, or the combination of anti-PD-1 and non-targeted IL-18 IC. All mice that were cured of their initial tumors rejected rechallenge with MC38 implantation, confirming the development of long-term immunologic memory induced by BPT567.

The abstract will be made available for viewing on Bright Peak’s website upon presentation at the AACR 2023 Annual Meeting (www.brightpeaktx.com).

About Bright Peak Therapeutics

Bright Peak Therapeutics is a biotechnology company advancing a portfolio of multifunctional immunotherapies for the treatment of patients with cancer and autoimmune disease. We accomplish this by leveraging our world class protein engineering capabilities and our unique cell-free technology platform to chemically synthesize and conjugate novel protein therapeutics that reflect state-of-the-art insights into cytokine and immune checkpoint biology. Our pipeline stretches from discovery to IND-enabling and encompasses antibody-cytokine conjugates and other novel formats. Bright Peak is based in Basel, Switzerland and Del Mar, CA and is funded by a syndicate of leading healthcare investors.

Contact: info@brightpeaktx.com

GlobeNewswire Distribution ID 8808503

Matterport and AWS boost efficiency, safety, and innovation with unified 3D view of business operations

SUNNYVALE, April 17, 2023 (GLOBE NEWSWIRE) — Matterport, Inc. (Nasdaq: MTTR) announced the general availability of new integrations with AWS IoT TwinMaker, enabling enterprise customers to seamlessly connect Internet of Things (IoT) data into visually immersive and dimensionally accurate Matterport digital twins. AWS IoT TwinMaker is a solution from Amazon Web Services (AWS) that makes it easier for developers to create digital twins of real-world systems such as buildings, factories, industrial equipment, and production lines. This new offering from Matterport supports enterprise digital transformation efforts by providing customers with an efficient and cost-effective solution to remotely optimize building operations, increase production output, improve equipment performance, and increase environmental health and safety at their facilities.

“Working with Matterport, we’re now able to provide customers with seamless integration of their live IoT data into detailed, spatially-accurate digital twins,” said Yasser Alsaied, Vice President of IoT, AWS. “There’s an incredible opportunity for enterprise customers to embrace digital twins, especially those in manufacturing, energy, and smart building industries, to gain more insight into their operations while increasing efficiencies across the organization.”

The Matterport and AWS IoT TwinMaker integration is a reflection of the extensive relationship between Matterport and AWS, allowing AWS customers to link real-time operational data into Matterport’s 3D digital twins to simplify the management of complex data sets. Global polymer and chemical manufacturer, INVISTA, one of the world’s largest integrated producers of polymers and fibers, is already using the integration to enable remote monitoring and collaboration, predictive maintenance and virtual training to reduce expenses and significantly increase operational efficiencies.

“With a digital twin of our manufacturing operations, our connected field personnel can proactively enable consistently high performance of our plant assets,” said Jerry Grunewald, Vice President of Operations Transformation, INVISTA. “AWS IoT TwinMaker and Matterport digital twins provide us with a 3D visualization of our facilities for a unified view of live sensor data, equipment maintenance records, and engineering design information that enable us to make effective decisions quickly.”

This integration offers new capabilities to further enable digital twin technology in the enterprise, serving customers at any stage of their digital transformation journey. Real-time operational data is integrated within Matterport’s digital twins to provide a single, unified visual representation of any physical environment and relevant, related data.

Customers using Matterport with AWS IoT TwinMaker can experience several benefits to reduce costs and improve operational efficiencies, including:

• Simplifying the process to create digital representations of physical environments.
• Increasing productivity by enabling consistent high performance of facility assets and streamlining the management of complex data sets.
• Improving field operations in manufacturing plants with real-time IoT sensor and process data.
• Increasing equipment uptime in remote facilities by analyzing trends and predicting issues or maintenance needs.
• Providing remote training and expert instruction to frontline workers.
• Reducing site visits and carbon footprint to realize lower operational costs, sustainability goals, and reduce risk of injury.

“Enterprise businesses are embracing the significant opportunity for digital twins to transform how they manage manufacturing and operational facilities at a global scale,” said RJ Pittman, Chairman and CEO, Matterport. “For environments with heavy machinery, Matterport and AWS have created a new paradigm for managing and training a frontline workforce, creating a safer experience for employees that benefits the bottom line.”

Learn more about how organizations can take advantage of digital twins in their operations: https://matterport.com/partners/amazon-web-services

About Matterport
Matterport, Inc. (Nasdaq: MTTR) is leading the digital transformation of the built world. Our groundbreaking spatial data platform turns buildings into data to make nearly every space more valuable and accessible. Millions of buildings in more than 177 countries have been transformed into immersive Matterport digital twins to improve every part of the building lifecycle from planning, construction, and operations to documentation, appraisal and marketing. Learn more at matterport.com and browse a gallery of digital twins.

©2023 Matterport, Inc. All rights reserved. Matterport is a registered trademark and the Matterport logo is a trademark of Matterport, Inc. All other marks are the property of their respective owners.

Media Contact:
Charlie Stager
Director, Communications
press@matterport.com

Investor Contact:
Mike Knapp
VP, Investor Relations
ir@matterport.com

GlobeNewswire Distribution ID 8808432

Map of Arbor Metal Corp.’s Jarnet Lithium Claims

Arbor’s Jarnet Lithium Mine is located in the James Bay region of Quebec and is comprised of 47 map-designated claims that cover an approximate area of 3,759 hectares.

VANCOUVER, British Columbia, April 17, 2023 (GLOBE NEWSWIRE) — Arbor Metals Corp. (the “Company” or “Arbor“) (TSXV: ABR, FWB: 432) announces that it has initiated DIRT Exploration of Cape Town, South Africa, to carry out a long-wave infrared survey (“LWIR“) and interpretation of high-resolution satellite imagery over the four blocks comprising the Company’s Jarnet Lithium Project and surrounding area in the James Bay region of Quebec. The Jarnet Lithium Project covers approximately 3,759 hectares and comprises 70 map-designated claims.

Located less than two km northwest of Patriot Battery Metals Inc.’s (“PMET”) CV-5 pegmatite target, the Jarnet South block is the subject of Arbor’s ongoing exploration efforts. PMET recently reported (PMET news release, March 29th, 2023) a high-grade extension (Nova Zone) of the CV 5 target of 87.7 metres averaging 3.13 per cent Li2O (lithium oxide), including 19.8 metres of 5.28 per cent Li2O.

LWIR analysis has the ability to map or identify mineral distribution over extensive areas covered by foliage and shallow cover through reflectance spectroscopy against a set of known standards and proprietary processing of satellite data. The LWIR analysis can view mineral spectra to shallow depths, thanks to its ground-penetrating nature, utilizing the long-wave bands of infrared radiation. This survey, together with satellite imagery analysis, will incorporate data and known pegmatite occurrences that have been identified from the Company’s 2022 reconnaissance-scale field program.

Arbor is currently compiling existing assessment and regional data on the four Jarnet claim blocks and surrounding properties. While some of the neighbouring properties have received limited attention on lithium mineralization, there is available geological and geophysical assessment data relating to exploration for base (Cu, Zn, Pb) and precious (Au, Ag) metal targets. The Jarnet South Block has southern and eastern boundaries contiguous with PMET Corvette Property, while the North Block is contiguous to PMET’s Corvette Property on the southwest boundary.

The DIRT interpretive report and the Company’s compilation will be used to refine proposed exploration targets on the Jarnet Project for the 2023 field season.

Note: The Company cautions the discoveries and observations on properties in proximity to the Company’s properties are not necessarily indicative of the presence of similar mineralization or geology on the company’s properties.

Dr. Peter Born, P.Geo., is the designated qualified person as defined by National Instrument 43-101 and is responsible for and has approved the technical information in this release.

About Arbor Metals Corp.

Arbor Metals Corp. is a mining exploration company that focuses on developing high-value mineral projects of geographic significance across the globe. As a leader in the industry, the company is dedicated to advancing mineral exploration and overseeing world-class mining projects. Arbor is confident that quality projects, proven strategies, and a professional team will lead to exceptional outcomes. Currently, the company holds three exceptional mineral projects.

One of these mineral projects is the Jarnet Lithium Project, which is located in the James Bay region of Quebec and is comprised of 47 map-designated claims that cover an approximate area of 3,759 hectares. The Jarnet Project is contiguous to the Corvette-FCI property, where diamond drilling has confirmed significant lithium mineralization and represents one of the most high-profile lithium exploration projects in the sector.

For more information, interested parties may contact Mark Ferguson, Chief Executive Officer, by sending an email to info@arbormetals.com or by visiting the company’s website at www.arbormetalscorp.com.

On behalf of the Board,

Arbor Metals Corp.

Mark Ferguson, Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When or if used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target”, “plan”, “forecast”, “may”, “schedule” and similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to the development of the Jarnet Lithium Project, the assessment of samples from that Project, and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance, or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3618b042-01cc-4fdc-9dc6-19987e9bc55d

GlobeNewswire Distribution ID 8808489

Turin, 14^th April 2023. Iveco Group N.V. (MI: IVG) (the Company or IVG) announces that its shareholders approved all the resolutions proposed by the Board of Directors (the Board) at their Annual General Meeting (AGM) held today in Amsterdam, the Netherlands.

The AGM:

• adopted the 2022 Annual Financial Statements;
• expressed a majority of votes in favour of the Remuneration Report for the Financial Year 2022;
• granted Executive and Non-Executive Directors discharge from liability for the exercise of their duties in the Financial Year 2022;
• reappointed Suzanne Heywood and Gerrit Marx as Executive Directors, and Tufan Erginbilgic, Essimari Kairisto, Linda Knoll, Alessandro Nasi, Olof Persson, Benoît Ribadeau-Dumas and Lorenzo Simonelli as Non-Executive Directors of the Company. Subsequently, the Board confirmed Ms Heywood, Mr Marx and Mr Simonelli as Chairperson, Chief Executive Officer and Senior Non-Executive Director, respectively;
• authorised the Board to repurchase up to 10,000,000 Common Shares with a maximum total allocation of €130,000,000 for a period of 18 months from the date of the AGM.

Details of all matters discussed today at the AGM are available on the Company’s website (www.ivecogroup.com), where the Chairperson’s and the Chief Executive Officer’s presentations, as well as the voting results, will be posted shortly.

Concurrently, the Company published its 2022 Sustainability Report, which is available on the corporate website (www.ivecogroup.com).

This is Iveco Group’s first Sustainability Report as an independent Company. It was written in line with multiple international reporting requirements and sustainability reporting guidelines, and it outlines Iveco Group’s plan to become increasingly sustainable and the Company’s ESG achievements in 2022.

The Company also announces that it launches today an initial tranche (up to € 55,000,000) of its share buyback program with the aim of repurchasing up to 10,000,000 Common Shares for a maximum total allocation of € 130,000,000 for the whole buyback initiative, as outlined above.

The initial tranche of the buyback program will end on 20^th December 2023 (subject to suspension or early termination) and will be carried out pursuant to the terms and conditions of the authorisation granted at the AGM, in compliance with all applicable laws and regulations including the European Commission Regulation (EU) 596/2014 and the Commission Delegated Regulation (EU) 2016/1052. The Company has engaged a primary financial institution as the intermediary to manage the purchase of IVG Common Shares on Euronext Milan and on multilateral trading facilities; this financial institution will make its trading decisions independent of the Company. The repurchased Common Shares will be used to meet the Company’s obligations under its equity incentive plans, as existing from time to time.

Any changes to the information above will be promptly disclosed. The Company will report on the progress of the purchases in accordance with the applicable rules.

As of today, the Company holds in treasury 71,945 Special Voting Shares, and no Common Shares. No IVG shares are held by entities the Company controls.

Iveco Group N.V. (MI: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a major force in its specific business: IVECO, a pioneering commercial vehicles brand that designs, manufactures, and markets heavy, medium, and light-duty trucks; FPT Industrial, a global leader in a vast array of advanced powertrain technologies in the agriculture, construction, marine, power generation, and commercial vehicles sectors; IVECO BUS and HEULIEZ, mass-transit and premium bus and coach brands; IDV, for highly-specialised defence and civil protection equipment; ASTRA, a leader in large-scale heavy-duty quarry and construction vehicles; MAGIRUS, the industry-reputed firefighting vehicle and equipment manufacturer; and IVECO CAPITAL, the financing arm which supports them all. Iveco Group employs more than 35,000 people around the world and has 26 manufacturing plants and 29 R&D centres. Further information is available on the Company’s website www.ivecogroup.com

Media Contacts:
Francesco Polsinelli, Mob: +39 335 1776091
Fabio Lepore, Mob: +39 335 7469007
E-mail: mediarelations@ivecogroup.com

Investor Relations:
Federico Donati, Tel: +39 011 0073539
E-mail: investor.relations@ivecogroup.com

Attachment

• 20230414_PR_Iveco_Group_AGM_Results_Launch_Share_Buyback_Program

GlobeNewswire Distribution ID 1000803927

KUALA LUMPUR, Malaysia, April 13, 2023 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global”, or the “Company”) a multi-disciplinary consulting group with key advisory practices in the areas of business and technology, announced that its ordinary shares have commenced trading on The Nasdaq Capital Market today under the ticker symbol “VCIG.” The shares closed their first day of trading above the offering price at $4.25.

On April 13, 2023, the Company priced its firm commitment underwritten public offering (the “Offering”) of 1,280,000 shares of ordinary shares at a public offering price of $4.00 per share. The gross proceeds to the Company were $5,120,000 before deducting underwriting discounts, commissions and other Offering expenses.

Boustead Securities, LLC and Sutter Securities, Inc. acted as the underwriters for the firm commitment Offering.

A registration statement on Form F-1, as amended (File No. 333-268109), filed by the Company with the Securities and Exchange Commission (the “SEC”), was declared effective on March 30, 2023. The Offering has been made only by means of a prospectus. A copy of the final prospectus related to the Offering may be obtained, when available, from Boustead Securities, LLC, via email: offerings@boustead1828.com, or by calling +1 (949) 502-4408, or by standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 395, Irvine, CA 92618, USA. In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About VCI Global Limited

VCI Global is a multi-disciplinary consulting group with key advisory practices in the areas of business and technology. The Company provides business and boardroom strategy services, investor relation services, and technology consultancy services. Its clients range from small-medium enterprises and government-linked agencies to publicly traded companies across a broad array of industries. VCI Global operates solely in Malaysia, with clients predominantly from Malaysia, but also serves some clients from China, Singapore, and the US.

For more information on the Company, please log on to https://v-capital.co/.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company’s ability to achieve profitable operations, customer acceptance of new products, the effects of the spread of Coronavirus (COVID-19) and future measures taken by authorities in the countries wherein the Company has supply chain partners, the demand for the Company’s products and the Company’s customers’ economic condition, the impact of competitive products and pricing, successfully managing and general economic conditions and other risk factors detailed in the Company’s filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law.

CONTACT INFORMATION:

Issued by Imej Jiwa Communications Sdn Bhd and ICR Inc. on behalf of VCI Global Limited
For media queries, please contact:

Imej Jiwa Communications Sdn Bhd
Chris Chuah
Email: chris@imejjiwa.com

ICR Inc.
Investor Relations
Michael Bowen
Vciglobal.ir@icrinc.com

Public Relations
Brad Burgess
Vciglobal.pr@icrinc.com

Boustead Securities, LLC
Underwriter
Dan McClory, Head of Equity Capital Markets
dan@boustead1828.com

GlobeNewswire Distribution ID 8807809